Isoniazid, rifampin, and pyrazinamide plasma concentrations in relation to treatment response in Indonesian pulmonary tuberculosis patients. - Wikidata - wikimedia - TriplyDB

Isoniazid, rifampin, and pyrazinamide plasma concentrations in relation to treatment response in Indonesian pulmonary tuberculosis patients.

Isoniazid, rifampin, and pyrazinamide plasma concentrations in relation to treatment response in Indonesian pulmonary tuberculosis patients.

http://www.wikidata.org/entity/Q34729493

about

Advanced Therapeutic Strategies for Chronic Lung Disease Using Nanoparticle-Based Drug Delivery Pharmacokinetic-Pharmacodynamic modelling of intracellular Mycobacterium tuberculosis growth and kill rates is predictive of clinical treatment duration Plasma drug activity in patients on treatment for multidrug-resistant tuberculosis Concentration-Dependent Antagonism and Culture Conversion in Pulmonary Tuberculosis.Effects of dosage, comorbidities, and food on isoniazid pharmacokinetics in Peruvian tuberculosis patients Pharmacokinetics of first-line antituberculosis drugs in HIV-infected children with tuberculosis treated with intermittent regimens in India.Subtherapeutic concentrations of first-line anti-TB drugs in South African children treated according to current guidelines: the PHATISA study.Exposure to total and protein-unbound rifampin is not affected by malnutrition in Indonesian tuberculosis patients.Limited sampling strategy and target attainment analysis for levofloxacin in patients with tuberculosis.Global Urine Metabolomics in Patients Treated with First-Line Tuberculosis Drugs and Identification of a Novel Metabolite of Ethambutol Pharmacokinetics of Antituberculosis Drugs in HIV-Positive and HIV-Negative Adults in Malawi.Evaluation of high-dose rifampin in patients with new, smear-positive tuberculosis (HIRIF): study protocol for a randomized controlled trial.Serum Levels of Antituberculosis Drugs and Their Effect on Tuberculosis Treatment Outcome.HIV-1 Coinfection Does Not Reduce Exposure to Rifampin, Isoniazid, and Pyrazinamide in South African Tuberculosis Outpatients.Adequacy of Rifampin Absorption after Jejunostomy Tube Administration.Therapeutic drug monitoring in the treatment of tuberculosis: an update.Pharmacologic considerations in use and development of antituberculosis drugs.Evaluation of the Adequacy of the 2010 Revised World Health Organization Recommended Dosages of the First-line Antituberculosis Drugs for Children.Optimizing treatment outcome of first-line anti-tuberculosis drugs: the role of therapeutic drug monitoring.The challenges of pharmacokinetic variability of first-line anti-TB drugs.Suboptimal Exposure to Anti-TB Drugs in a TBM/HIV+ Population is not Related to Anti-retroviral Therapy.Simultaneous quantification of isoniazid, rifampicin, ethambutol and pyrazinamide by liquid chromatography/tandem mass spectrometry.Tenofovir DF/emtricitabine and efavirenz combination therapy for HIV infection in patients treated for tuberculosis: the ANRS 129 BKVIR trial.Cohort profile of a study on outcomes related to tuberculosis and antiretroviral drug concentrations in Uganda: design, methods and patient characteristics of the SOUTH study.Clinical significance of 2 h plasma concentrations of first-line anti-tuberculosis drugs: a prospective observational study.Factors Influencing Tuberculosis Treatment Outcome in Adult Patients Treated with Thrice-Weekly Regimens in India.Strategy to limit sampling of antituberculosis drugs instead of determining concentrations at two hours postingestion in relation to treatment response.Reply to "strategy to limit sampling of antituberculosis drugs instead of determining concentrations at two hours postingestion in relation to treatment response".Population Pharmacokinetics of Pyrazinamide in Patients with Tuberculosis.A rifapentine-containing inhaled triple antibiotic formulation for rapid treatment of tubercular infection.Pharmacokinetics and pharmacogenetics of anti-tubercular drugs: a tool for treatment optimization?Pharmacokinetics of second-line anti-tuberculosis drugs in children with multidrug-resistant tuberculosis in India.Delayed Sputum Conversion in TB-HIV Co-Infected Patients with Low Isoniazid and Rifampicin Concentrations.The utility of pharmacokinetic studies for the evaluation of exposure-response relationships for standard dose anti-tuberculosis drugs The importance of clinical pharmacokinetic-pharmacodynamic studies in unraveling the determinants of early and late tuberculosis outcomes

P2860

Q28076132-04384131-E399-43DC-A6E0-53C6F78DCB7A Q30377051-DEA5899A-7CAA-476C-A6B4-26B71C20B87F Q30411475-ECAC57F6-9E70-41DB-A087-9CC65E70F0A9 Q33621748-2D3D656F-B50D-4C3E-8B99-B0BD41C52414 Q34597564-8318CB87-61AE-4774-AFD5-B07C3709874A Q35105834-962BC14E-145C-49A3-9A97-CEA229B18C8D Q35167178-8E062D7F-3242-4925-B3B9-6371A5940518 Q35584822-2E1EA5B1-6381-4395-9839-2A21EDD9503D Q35746184-18411727-DF25-479D-AC9C-08FBF38EBA8C Q35911355-BFA4F68D-4CAB-452C-A7DB-032D8531048F Q36075981-CC9CB3B6-FEAF-460C-B74D-1641CE8233BC Q36115081-BE99EE40-53FC-4B42-A2BA-57E1E3AD7856 Q36439129-158A2C84-7F6E-45C9-B681-57BCC1BF99F1 Q37287701-7D7CF0D5-58CB-421F-A3D4-F4D6A139E024 Q37352344-1ACF1DDE-588D-4826-B931-23E3F02016D3 Q38213320-1752DA59-4D33-434C-A973-07EAF747594F Q38252559-AFD9F6CA-E46D-45E6-AF4B-425652E272C2 Q38673843-0AFCACBD-3199-47AC-9D02-F78928E0FC3E Q38865905-B668B6D0-9E13-491C-85C7-3328BDE30F55 Q38977166-314CEEF5-3AA7-4028-AA23-2CD0F4049ADF Q39539828-070FAAD3-2BDE-47E3-83AD-20065267CC8A Q40568451-51EF07E9-74E2-446B-AF7D-11162B67A48E Q40867178-8D1495F7-6EE2-489B-822C-AA2EA33FDCEF Q41996343-528138DB-3425-4724-B311-BFDE572718AB Q42201109-9CAEEDBA-9EE1-460B-82B6-A5AF56828865 Q42358805-F9EE53FE-F767-462A-8629-2AE760614D4F Q42693597-7F1446E6-9F21-4C00-812C-FF4FDA981DFF Q42695119-E54AA728-8C76-43E2-AFA1-6D7300683ACF Q45199376-EA8130CE-9367-4216-9AB5-C4ABFDF20DA1 Q46650295-DD66D2A1-CD50-405E-8004-5D054810AF33 Q47332682-49BDE85C-1585-46E2-A8E9-2C5713808273 Q49792011-D2B6B1A4-EA45-4AC1-BCBF-943BF3912B71 Q52669182-93B7E589-F28B-43A9-968E-398A1F344EB5 Q56912878-887695CC-49A3-435F-B5C1-A2C6F5B5D185 Q57152709-B125AA5A-175D-435E-A631-FB86B3DE03F2

P2860

Isoniazid, rifampin, and pyrazinamide plasma concentrations in relation to treatment response in Indonesian pulmonary tuberculosis patients.

http://www.wikidata.org/entity/Q34729493

description

2013 nî lūn-bûn

@nan

2013 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Isoniazid, rifampin, and pyraz ...... lmonary tuberculosis patients.

@ast

Isoniazid, rifampin, and pyraz ...... lmonary tuberculosis patients.

@en

Isoniazid, rifampin, and pyraz ...... lmonary tuberculosis patients.

@nl

type

label

Isoniazid, rifampin, and pyraz ...... lmonary tuberculosis patients.

@ast

Isoniazid, rifampin, and pyraz ...... lmonary tuberculosis patients.

@en

Isoniazid, rifampin, and pyraz ...... lmonary tuberculosis patients.

@nl

prefLabel

Isoniazid, rifampin, and pyraz ...... lmonary tuberculosis patients.

@ast

Isoniazid, rifampin, and pyraz ...... lmonary tuberculosis patients.

@en

Isoniazid, rifampin, and pyraz ...... lmonary tuberculosis patients.

@nl

P1433

Q34729493-87C690B0-D520-4D53-ABA4-AB0F5309BB75

P1476

Q34729493-9983236B-0253-4C69-B592-DA423620D01B

P2093

Q34729493-94A1DEE9-AF0C-4E1F-A99C-B1983E5D160E

Q34729493-B91B7CCE-4F05-48CD-BCCB-834565669CB3

Q34729493-C834A71C-2E49-4373-AD77-0A56A9B278D1

Q34729493-CA789827-98A6-4F99-AC7F-A3C09CE3F8C4

Q34729493-E5E90CDA-54AB-46CC-8463-67B9B6B77D3C

Q34729493-FA817275-CC33-4744-B47C-3598EE7A8CFF

Q34729493-FB6E703F-6B08-4424-8722-B73FC3839348

Q34729493-FC7130D8-5810-4384-90D8-94D30E721ABC

P2860

Q34729493-090B6918-8087-410E-8257-5E3F4ACFF509

Q34729493-0DE853BE-245D-47EA-97FA-E1CD7D3FA6DA

Q34729493-13430108-20D7-430B-AE14-E1A7792B771F

Q34729493-1F754CA8-F4DF-4E10-825F-CA6A5C195A59

Q34729493-241A8111-0A6C-4838-A7EF-C0E792CDE35F

Q34729493-29ECFFAB-0BF9-4F6C-8378-EB8B74780E71

Q34729493-402220C0-A513-49C9-983D-BAC3EDD53178

Q34729493-40699A12-6785-4E3B-A51A-542A505ABDDD

Q34729493-54ABEA32-8DE6-4DBD-81E6-296300E67CDC

Q34729493-5C0674F4-95A2-4136-8006-53556E95EA46

P304

Q34729493-F8F628CB-2C84-43AA-A6E3-D3884EB3ABCB

P31

Q34729493-47717091-F4DE-40B4-B164-3EA963A33A7C

P356

Q34729493-1CFDC316-C4C1-4B20-BE51-330AF5BB244D

P407

Q34729493-9CD7FF3A-86EA-41A9-803D-707468DDBA4D

P433

Q34729493-12F96DC8-52F2-4900-AD2E-67C1EDA6C61B

P478

Q34729493-4CF0B7B5-2FC3-4F28-B002-4EA5855A7642

P50

Q34729493-C5C8E041-ACFA-4EA0-A512-8CE7A2620E3F

P577

Q34729493-1AE2D28B-FA8A-4333-8C28-927075161815

P698

Q34729493-4CCCE340-35E8-4E72-BB8E-61AADDF54E41

P921

Q34729493-78279117-D489-42E0-82C4-5FF88E6982A9

Q34729493-91A0D07E-C555-4838-B250-1F3A1E7CA8CD

Q34729493-D2AF7367-F587-43BC-A21A-26CAB0500B43

P932

Q34729493-638F0642-E7D5-4691-9D2B-E750DC47EE20

P356

P1433

Antimicrobial Agents and Chemotherapy

P1476

Isoniazid, rifampin, and pyraz ...... lmonary tuberculosis patients.

@en

P2093

Arum Ginanjar

http://www.w3.org/2001/XMLSchema#string

Carolien Ruesen

http://www.w3.org/2001/XMLSchema#string

Erlina Burhan

http://www.w3.org/2001/XMLSchema#string

Hadiarto Mangunnegoro

http://www.w3.org/2001/XMLSchema#string

Purwantyastuti Ascobat

http://www.w3.org/2001/XMLSchema#string

Rob Aarnoutse

http://www.w3.org/2001/XMLSchema#string

Rogier Donders

http://www.w3.org/2001/XMLSchema#string

Rovina Ruslami

http://www.w3.org/2001/XMLSchema#string

P2860

Role of individual drugs in the chemotherapy of tuberculosis

Pharmacokinetics and tolerability of a higher rifampin dose versus the standard dose in pulmonary tuberculosis patients.

The effect of type 2 diabetes mellitus on the presentation and treatment response of pulmonary tuberculosis.

Pharmacokinetics of antituberculosis drugs in pulmonary tuberculosis patients with type 2 diabetes

Determinants of rifampin, isoniazid, pyrazinamide, and ethambutol pharmacokinetics in a cohort of tuberculosis patients.

Exposure to rifampicin is strongly reduced in patients with tuberculosis and type 2 diabetes.

Dose-dependent activity of pyrazinamide in animal models of intracellular and extracellular tuberculosis infections.

Therapeutic drug monitoring in the treatment of tuberculosis.

Pharmacokinetics-pharmacodynamics of rifampin in an aerosol infection model of tuberculosis.

Therapeutic drug monitoring in the treatment of active tuberculosis

P304

3614-3619

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.02468-12

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

57

http://www.w3.org/2001/XMLSchema#string

P50

Reinout van Crevel

P577

2013-05-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23689725

http://www.w3.org/2001/XMLSchema#string

P921

Akafuba bulwadde

P932

3719785

http://www.w3.org/2001/XMLSchema#string